Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.

Abstract

Imiquimod, a TLR7 agonist, is a novel immune response modifier currently widely used in the treatment of actinic keratoses (in situ squamous cell carcinoma). Imiquimod has revolutionized the treatment of field cancerization and has been approved for the treatment of superficial basal cell carcinoma with the recommendation of a 6-week treatment strategy, offering an alternative to surgery or other destructive treatment strategies.

• Authors: Dimitrios Papakostas, Eggert Stockfleth
• Journal: Future oncology (London, England) (Future Oncol) Vol. 11 Issue 22 Pg. 2985-90 (Nov 2015) ISSN: 1744-8301 [Electronic] England
• PMID: 26450707 (Publication Type: Journal Article, Review)

Chemical References

• Aminoquinolines
• Antineoplastic Agents
• Immunologic Factors
• Imiquimod

Topics

• Administration, Topical
• Aminoquinolines (administration & dosage)
• Antineoplastic Agents (administration & dosage, adverse effects, chemistry, pharmacokinetics)
• Carcinoma, Basal Cell (drug therapy, pathology)
• Clinical Trials as Topic
• Humans
• Imiquimod
• Immunologic Factors (administration & dosage, adverse effects, chemistry, pharmacokinetics)
• Neoplasm Staging
• Product Surveillance, Postmarketing
• Skin Neoplasms (drug therapy, pathology)
• Treatment Outcome